Program Description & Educational Objectives
In this case-based activity, an expert in the management of major depressive disorder (MDD) discusses the practical applications of measurement-based care as well as strategies for the management of patients who are either nonresponsive or suboptimal responders to treatment. Additional highlights of this activity include a review of evidence-based treatment guidelines, considerations for therapeutic selection, and a discussion of available tools for assessing the impact of treatment-related side effects as well as treatment adherence in patients with MDD.
Upon completion of this activity, participants will be able to:
- Apply recent guidelines for the management of patients with major depressive disorder
- Develop strategies to implement measurement-based care for the treatment and monitoring of patients with major depressive disorder
- Employ various pharmacologic and nonpharmacologic strategies to achieve remission in patients with major depressive disorder who do not optimally respond to initial therapy for treatment-refractory depression
Target Audience
This activity has been designed to meet the educational needs of psychiatrists, psychiatric physician assistants and advanced practice nurses, internal medicine and family practice physicians, and other clinicians involved in the management of adult patients with major depressive disorder.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: February 17, 2012 - February 16, 2013
Time to Complete PeerView inPractice: 60 minutes
Faculty & Disclosure / Conflict of Interest Policy
All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Course Directors and Interviewees
Ian A. Cook, MD
Joanne & George Miller and Family Professor of Psychiatry
Director, UCLA Depression Research and Clinic Program
Semel Institute for Neuroscience and Human Behavior at UCLA
University of California, Los Angeles
Los Angeles, California
Ian A. Cook, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Neuronetics, Inc.; NeuroSigma, Inc.; U.S. Department of Defense; and U.S. Department of Justice.
Grant/Research Support from Aspect Medical Systems/Covidien; National Institutes of Health; Neuronetics, Inc.; Seaside Therapeutics; and Sepracor Inc.
Speakers Bureau participant with Neuronetics, Inc.
Honorarium from NeuroSigma, Inc.
Other Financial or Material Support from biomedical IP assigned to University of California.
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine
Boston University School of Medicine
Boston, Massachusetts
Larry Culpepper, MD, MPH,
has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Pharmaceuticals LP; Labopharm Inc.; Pfizer Inc; and Trovis Pharmaceuticals LLC.
Speakers Bureau participant with Merck & Co., Inc. Dr. Culpepper has made presentations regarding a federally funded study of methods to reduce hospital readmissions (with no mention of
pharmaceuticals).
Content Director
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education
Kirk A. Tacka, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Case-Based CME
The Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Performance Improvement CME
The Purdue University College of Pharmacy designates this PI CME activity for a maximum of 20.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Purdue University Continuing Nursing Education, West Lafayette, IN (ISNA No. CNEP 11-03, Exp. 06/1/2014) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity has been approved for 1.0 contact hour(s).
This CME/CNE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from 
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.